Matthias Kloor

Matthias Kloor, PD Dr. med. is a physician scientist who has been working in the field of molecular pathology, tumor immunology, and pathogenesis of hereditary cancer for more than a decade.

His research interests are dedicated to molecular models of tumor formation and their transfer into the clinical application, with a main focus on tumor immunology and immunological approaches for cancer prevention and treatment.

During the last 10 years as leader of the research group ‘Immune biology of microsatellite-unstable cancer’ he focused on the identification of relevant neoantigens specifically generated in microsatellite-unstable (MSI-H) cancers. These research activities have led to the first-in-human clinical trial examining a frameshift peptide neoantigen vaccine in MSI-H cancer patients. He complements the studies on cancer vaccines by examining mechanisms of immune evasion that allow MSI-H tumors to develop in spite of pronounced anti-tumoral immune responses.

Scientific career

  • 2000-2002: Residency at the Division of Molecular Diagnostics and Therapy, Department of Surgery, University of Heidelberg
  • 2003: Doctoral Thesis in Medicine
  • 2002-2006: Postdoctoral fellowship at the Department of Molecular Pathology, University of Heidelberg. Research project:
    • Molecular pathogenesis of colorectal cancer: Diagnostics and research on hereditary colorectal cancer
  • 2007-present: Leader of the research group ‘Immune biology of microsatellite-unstable cancer’, Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg. Research projects:
    • Immune biology and immune evasion of microsatellite-unstable colorectal cancer
    • Molecular diagnostics of hereditary colorectal cancer, Center of Familial Colorectal Cancer, University Hospital Heidelberg
    • Development of a vaccine to treat and prevent Lynch syndrome-associated cancers
    • Tumor initiation and precancerous lesions in Lynch syndrome
  • 2012: Habilitation in Applied Tumor Biology, ‘The pathogenesis of microsatellite unstable colorectal cancer and the evaluation of novel diagnostic and therapeutic options’


  • Lectures and seminars at Medical Faculty, University Heidelberg:
    • Molecular pathogenesis of cancer and its impact on clinical course of the disease and clinical decision making, since 2002
    • Hereditary cancer diagnostics and clinical management, since 2011
  • Conception and strategic planning of a new lecture series and practical laboratory training ‘tumor biology’, regular lectures and seminars at Faculty for Biosciences, University Heidelberg, since 2011
  • Many other lectures and teaching activities including Czerny Society (University Hospital Heidelberg) and Comenius lectures, since 2007


  • >120 papers in peer-reviewed journals
  • 18 first authorships (cumulative IF: 102.4)
  • 18 senior authorships (cumulative IF: 75.7)
  • 12 review articles, 3 book chapters
  • h-index: 37


  • Associate Editor, BMC Cancer (since 2012)
  • Editor and reviewer for Lancet Oncology, Oncogene, Gut, Clinical Cancer Research, Journal of Pathology, International Journal of Cancer